School of Medicine
Showing 3,881-3,900 of 4,930 Results
-
David Schneider
Professor of Microbiology and Immunology
Current Research and Scholarly InterestsWe study innate immunity and microbial pathogenesis. We have been studying models for a variety of bacterial infections including: Listeria, Mycobacteria, Salmonella and Streptococcus as well as some fungi, malaria and viruses. Our current focus is to determine how we recover from infections.
-
Logan Schneider
Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsFrom a research perspective, my long-term career plan is to refine the understanding of normal and dysfunctional sleep, much like the Epilepsy Phenome/Genome Project (EPGP) and Epi4K are doing for the enigmatic epilepsies. Insufficient sleep has been deemed a public health problem with poorly understood behavioral and physiologic sleep disorders lying at the core of the issue. I am currently using well-defined distinct and objective phenotypes (e.g. periodic limb movements, hypocretin-deficient narcolepsy) to acquire the analytic skills necessary to expand my knowledge of both signal processing and genetics, with the former enhancing my ability to identify and/or refine sleep phenotypes, and the latter facilitating the pathophysiological understanding of these phenotypes. As a consequence of a better link between symptoms/phenotypes, physiology, and genetic risks, more personally targeted and effective therapeutics can be developed to address the enriched spectrum of sleep disorders.
-
Ingela Schnittger, MD
Professor of Medicine (Cardiovascular)
Current Research and Scholarly InterestsMy main research continues to be in the field of echocardiography. Several areas of research are currently being pursued.
-
Mark J. Schnitzer
Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor of Biology, of Applied Physics and of Neurosurgery
Current Research and Scholarly InterestsThe goal of our research is to advance experimental paradigms for understanding normal cognitive and disease processes at the level of neural circuits, with emphasis on learning and memory processes. To advance these paradigms, we invent optical brain imaging techniques, several of which have been widely adopted. Our neuroscience studies combine these imaging innovations with behavioral, electrophysiological, optogenetic and computational methods, enabling a holistic approach to brain science.
-
Gary Schoolnik
Professor of Medicine (Infectious Diseases), Emeritus
Current Research and Scholarly InterestsStructure-function analysis of bacterial adhesion proteins and toxins; design and synthesis of synthetic antigens; immunobiology of human papillomaviruses
-
Donald Schreiber
Associate Professor of Emergency Medicine at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsMy research group focuses on the diagnosis and treatment of cardiovascular emergencies including acute myocardial infarction, acute coronary syndrome and congestive heart failure. We have evaluated novel cardiac markers and point-of-care testing in clinical practice. Current projects also include the diagnosis and treatment of acute pulmonary embolism and deep venous thrombosis. Other interests include spinal cord injury, pneumonia and sepsis.
-
Alan Schroeder
Clinical Professor, Pediatrics
BioDr. Schroeder is the associate chief for research in the division of pediatric hospital medicine at Lucile Packard Children’s Hospital Stanford, and a clinical professor in the division of hospital medicine and the division of critical care. His research interests focus on identifying areas where we can “safely do less” in healthcare, striving to ensure that children get the healthcare that they need while avoiding excessive tests and treatments that only cause harm. Dr. Schroeder is currently involved in multiple projects involving common conditions and interventions in pediatrics. He serves as the Stanford PI for PEDSNet and is an Associate Editor for the journal Hospital Pediatrics. At Stanford he co-leads the residency clinical research scholarly concentration and the faculty Clinical Research Peer Scholarship Community. Dr. Schroeder provides clinical care for children in the PICU and the pediatric ward.
-
John S. Schroeder, MD
Professor (Clinical) of Medicine (Cardiovascular), Emeritus
Current Research and Scholarly Interests1. Clinical Pharmocology of Cardiovascular Drugs
(a) Calcium Channel Blockers
(b) Agents for Heart Failure
(c) Anti-atherosclerotic Effects of Cardiovascular Drugs, e.g. Calcium Channel Blockers
2. Cardiac Transplantation/Congestive Heart Failure
3. Coronary Artery Spasm -
Joseph Schroers-Martin
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.
-
Birgitt Schuele
Associate Professor (Research) of Pathology
Current Research and Scholarly InterestsThe Schuele lab focuses on neurogenetics, human stem cell modeling, and gene therapy approaches to uncover disease mechanisms and pathways involved in neurodegeneration in Parkinson's, Alzheimer's disease and related disorders.
-
Kevin Schulman
Professor of Medicine (Hospital Medicine), by courtesy, of Health Policy and of Operations, Information and Technology at the Graduate School of Business
BioDr. Schulman is a Professor of Medicine, and, by courtesy, Professor of Operations, Information and Technology at Stanford’s Graduate School of Business. He serves as Interim Division Co-Chief for the Division of Hospital Medicine at Stanford, and as an Associate Chair of the Department of Medicine. He is the Faculty Director of Stanford’s new applied master degree program, the Master of Science in Clinical Informatics Management program. He also serves as Deputy Director of the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and has an appointment in the Department of Health Policy (by courtesy).
Dr. Schulman is a health economist/health services researcher working at the intersection of business, medicine and technology. With over 500 publications, he has had a broad impact on several areas of health policy (Scopus h-index=81). His research has appeared in the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the editor-in-chief of Health Management, Policy and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Service Research (HSR).
He is a graduate of Dartmouth College, the New York University School of Medicine, and The Wharton Health Care Management Program. He is an elected member of ASCI and AAP. -
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
